|
1
|
Brahmer JR, Govindan R, Anders RA, Antonia
SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon
EB, et al: The Society for Immunotherapy of Cancer consensus
statement on immunotherapy for the treatment of nonsmall cell lung
cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang L, Shi SB, Zhu Y, Qian TT and Wang
HL: Long non-coding RNA ASAP1-IT1 promotes cell proliferation,
invasion and metastasis through the PTEN/AKT signaling axis in
non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 22:142–149.
2018.PubMed/NCBI
|
|
3
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NSCLC Meta-analyses Collaborative Group
and Arriagada R, ; Auperin A, Burdett S, Higgins JP, Johnson DH, Le
Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant
chemotherapy, with or without postoperative radiotherapy, in
operable non-small-cell lung cancer: Two meta-analyses of
individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu S, Zhao X, Wu S, Du R, Zhu Q, Fang H,
Zhang X, Zhang C, Zheng W, Yang J and Feng H: Overexpression of
B7-H3 correlates with aggressive clinicopathological
characteristics in non-small cell lung cancer. Oncotarget.
7:81750–81756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu T, Wu X, Chen T, Luo Z and Hu X:
Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem
cell-like phenotypes through repressing Wnt/β-catenin signaling.
Clin Cancer Res. 24:1748–1760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paliouras AR, Monteverde T and Garofalo M:
Oncogene-induced regulation of microRNA expression: Implications
for cancer initiation, progression and therapy. Cancer Lett.
421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo J, Feng Z, Huang Z, Wang H and Lu W:
MicroRNA-217 functions as a tumour suppressor gene and correlates
with cell resistance to cisplatin in lung cancer. Mol Cells.
37:664–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu L, Luo F, Liu Y, Liu X, Shi L, Lu X and
Liu Q: Posttranscriptional silencing of the lncRNA MALAT1 by
miR-217 inhibits the epithelial-mesenchymal transition via enhancer
of zeste homolog 2 in the malignant transformation of HBE cells
induced by cigarette smoke extract. Toxicol Appl Pharmacol.
289:276–285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z,
Wang J, Lu Y, Yu Q, Su H, et al: Histone deacetylase SIRT1
negatively regulates the differentiation ofinterleukin-9-producing
CD4+ T cells. Immunity. 44:1337–1349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grbesa I, Pajares MJ, Martínez-Terroba E,
Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio
R and Montuenga LM: Pression of sirtuin 1 and 2 is associated with
poor prognosis in non-small cell lung cancer patients. PLoS One.
10:e01246702015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han L, Liang XH, Chen LX, Bao SM and Yan
ZQ: SIRT1 is highly expressed in brain metastasis tissues of
non-small cell lung cancer (NSCLC) and in positive regulation of
NSCLC cell migration. Int J Clin Exp Pathol. 6:2357–2365.
2013.PubMed/NCBI
|
|
15
|
He S, Wang Z, Tang H, Dong J, Qu Y and Lv
J: miR-217 inhibits proliferation, migration, and invasion by
targeting SIRT1 in osteosarcoma. Cancer Biother Radiopharm.
34:264–270. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu L, Yang S and Wang J: miR-217 inhibits
the migration and invasion of HeLa cells through modulating MAPK1.
Int J Mol Med. 44:1824–1832. 2019.PubMed/NCBI
|
|
18
|
Jiang B, Zhu SJ, Xiao SS and Xue M:
miR-217 inhibits M2-Like macrophage polarization by suppressing
secretion of interleukin-6 in ovarian cancer. Inflammation.
42:1517–1529. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang CL, Zheng XL, Ye K and Xue M: Effects
of microRNA-217 on proliferation, apoptosis, and autophagy of
hepatocytes in rat models of CCL4-induced liver injury by targeting
NAT2. J Cell Physiol. 234:3410–3424. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C, Zhang Z and Qi D: Circular RNA
hsa_circ_0023404 promotes proliferation, migration and invasion in
non-small cell lung cancer by regulating miR-217/ZEB1 axis. Onco
Targets Ther. 12:6181–6189. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong S and Weber JD: Deacetylation of the
retinoblastoma tumour suppressor protein by SIRT1. Biochem J.
407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang C, Chen L, Hou X, Li Z, Kabra N, Ma
Y, Nemoto S, Finkel T, Gu W, Cress WD and Chen J: Interactions
between E2F1 and SirT1 regulate apoptotic response to DNA damage.
Nat Cell Biol. 8:1025–1031. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alves-Fernandes DK and Jasiulionis MG: The
role of SIRT1 on DNA damage response and epigenetic alterations in
cancer. Int J Mol Sci. 20:31532019. View Article : Google Scholar
|
|
26
|
Jiang W, Hou L, Wei J, Du Y, Zhao Y, Deng
X and Lin X: Hsa-miR-217 inhibits the proliferation, migration, and
invasion in non-small cell lung cancer cells via targeting SIRT1
and P53/KAI1 signaling. Balkan Med J. 37:208–214. 2020.PubMed/NCBI
|
|
27
|
Zhang L, Chen J, He Q, Chao Z, Li X and
Chen M: MicroRNA-217 is involved in the progression of
atherosclerosis through regulating inflammatory responses by
targeting sirtuin 1. Mol Med Rep. 20:3182–3190. 2019.PubMed/NCBI
|
|
28
|
Xia K, Zhang Y and Sun D: miR-217 and
miR-543 downregulation mitigates inflammatory response and
myocardial injury in children with viral myocarditis by regulating
the SIRT1/AMPK/NF-κB signaling pathway. Int J Mol Med. 45:634–646.
2020.PubMed/NCBI
|
|
29
|
Salomone F, Barbagallo I, Godos J, Lembo
V, Currenti W, Cinà D, Avola R, D'Orazio N, Morisco F, Galvano F
and Li Volti G: Silibinin restores NAD(+) levels and induces the
SIRT1/AMPK pathway in non-alcoholic fatty liver. Nutrients.
9:102017. View Article : Google Scholar
|
|
30
|
Patra KC, Weerasekara VK and Bardeesy N:
AMPK-mediated lysosome biogenesis in lung cancer growth. Cell
Metab. 29:238–240. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li C, Dong Y, Wang L, Xu G, Yang Q, Tang
X, Qiao Y and Cong Z: Ginsenoside metabolite compound K induces
apoptosis and autophagy in non-small cell lung cancer cells via
AMPK-mTOR and JNK pathways. Biochem Cell Biol. 97:406–414. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He K, Guo X, Liu Y, Li J, Hu Y, Wang D and
Song J: TUFM downregulation induces epithelial-mesenchymal
transition and invasion in lung cancer cells via a mechanism
involving AMPK-GSK3β signaling. Cell Mol Life Sci. 73:2105–2121.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan G, Ru Y, Wu K, Yan F, Wang Q, Wang J,
Pan T, Zhang M, Han H, Li X and Zou L: GOLM1 promotes prostate
cancer progression through activating PI3K-AKT-mTOR signaling.
Prostate. 78:166–177. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu
S, Buchan JR and Cho WC: Role of autophagy and apoptosis in
non-small-cell lung cancer. Int J Mol Sci. 18:3672017. View Article : Google Scholar
|
|
35
|
Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J,
Li Z, Chen B, Zhang X, Pan H, et al: MetaLnc9 facilitates lung
cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer
Res. 77:5782–5794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao W, Peng F, Shu M, Liu H, Hou X, Wang
X, Ye J, Zhao B, Wang K, Zhong C, et al: Isogambogenic acid
inhibits the growth of glioma through activation of the AMPK-mTOR
pathway. Cell Physiol Biochem. 44:1381–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong LX, Sun LL, Zhang X, Pan L, Lian LJ,
Chen Z and Zhong DS: Negative regulation of mTOR activity by
LKB1-AMPK signaling in non-small cell lung cancer cells. Acta
Pharmacol Sin. 34:314–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
